Vanguard Group Inc. Boosts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Vanguard Group Inc. raised its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 0.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 40,323,750 shares of the company’s stock after buying an additional 97,536 shares during the quarter. Vanguard Group Inc. owned about 10.48% of Moderna worth $1,676,662,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. State Street Corp lifted its position in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares in the last quarter. Amundi boosted its position in shares of Moderna by 79.8% in the 4th quarter. Amundi now owns 1,206,273 shares of the company’s stock worth $52,075,000 after purchasing an additional 535,273 shares in the last quarter. Two Sigma Advisers LP purchased a new position in Moderna during the 3rd quarter worth $23,825,000. Finally, Douglas Lane & Associates LLC increased its position in Moderna by 62.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after buying an additional 298,715 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Royal Bank of Canada restated a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Morgan Stanley decreased their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday, January 15th. Evercore ISI set a $50.00 target price on Moderna in a research report on Friday, February 14th. Barclays lowered Moderna from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Finally, UBS Group cut their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, February 19th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and an average price target of $59.00.

Moderna Trading Down 7.0 %

Shares of MRNA opened at $31.48 on Thursday. The firm has a market cap of $12.17 billion, a P/E ratio of -3.39 and a beta of 1.86. The stock’s 50 day moving average is $34.81 and its two-hundred day moving average is $45.02. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.